Fatty Liver, Nonalcoholic Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver
L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is
involved in transporting fatty acids across the mitochondrial membrane, it could be an
important component in treating a fatty liver disease.
The investigators conduct a study to evaluate the efficacy of the combination of L-Carnitine
and Magnesium as a treatment for fatty liver.
A phase 3, randomized, double blind placebo controlled study that evaluate the efficacy of
L-Carnitine and Magnesium as a treatment for fatty liver, 60 eligible patients with a
diagnosis of NAFDL will be randomly assigned in a 1:1 ratio to receive either the trial
product " SLIM WATER" that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks, or
placebo for the initial 8 weeks and continue another 8 weeks with the trial product "SLIM
WATER". `Follow up time is estimated to be 24 week based on monthly clinic visits and
accordingly assessment of lipid profile, weight and insulin resistance.
Fibrotest will be used at the beginning of the trial and at the end (week 16) comparing the
fat content before and after the treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05220956 -
Impact of Time-restricted Feeding in NAFLD
|
N/A | |
| Active, not recruiting |
NCT04067440 -
Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
|
||
| Completed |
NCT04509245 -
The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes
|
N/A | |
| Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
| Not yet recruiting |
NCT06117137 -
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT02132780 -
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
|
N/A | |
| Active, not recruiting |
NCT04241575 -
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
|
N/A | |
| Completed |
NCT02290106 -
Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
|
N/A | |
| Completed |
NCT03784716 -
Ketogenic Diet in Non-alcoholic Fatty Liver Disease
|
N/A | |
| Recruiting |
NCT05558592 -
Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)
|
N/A | |
| Active, not recruiting |
NCT06445335 -
Prevalence of NAFLD in T2DM Patients
|
N/A | |
| Active, not recruiting |
NCT05855239 -
Quantification of Hepatic Steatosis With Different Ultrasound Frequency
|
||
| Recruiting |
NCT05877547 -
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
|
Phase 2 | |
| Completed |
NCT04462562 -
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
|
N/A | |
| Completed |
NCT04054297 -
Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat
|
N/A | |
| Completed |
NCT03260543 -
Efficacy and Safety of Fermented Ginseng Powder on Liver Function
|
N/A | |
| Not yet recruiting |
NCT06215131 -
Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease
|
N/A | |
| Completed |
NCT03593343 -
Hepatic Glycogen and Fat Oxidation
|
N/A | |
| Recruiting |
NCT06257732 -
Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines
|
N/A | |
| Completed |
NCT02983669 -
The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease
|
N/A |